Roivant Sciences (ROIV) Bernstein 42nd Annual Strategic Decisions Conference summary

Business model and industry perspective

• Emphasizes a unique blend of insider and outsider expertise, focusing on asset acquisition and clinical development rather than early-stage lab science.

• Built pipeline primarily through business development and partnerships, especially with large pharma companies.

• Maintains ongoing focus on acquiring new assets, despite a robust current pipeline.

• Sees current biotech landscape as rich with innovation and opportunity, driven by advances in modalities and global shifts.

• Believes replenishing the pipeline is essential for survival in biopharma, likening it to a 'treading water' industry.

Pipeline highlights and launch strategies

• Preparing for commercial launch of brepocitinib in dermatomyositis, leveraging lessons from previous launches and focusing on patient support and referral center relationships.

• Expects slow and steady launch ramp for brepocitinib, with limited public disclosure of early KPIs due to commercial strategy.

• Targets poorly controlled steroid-dependent patients and those on off-label therapies as early adopters for brepocitinib.

• Maintains a competitive edge by being first to market in dermatomyositis, with VYVGART seen as a future but not immediate threat.

Clinical development and indication expansion

• NIU (non-infectious uveitis) phase III trial designed to address placebo risk and patient heterogeneity, with aggressive steroid tapering.

• Commercial opportunity in NIU remains strong even in HUMIRA-refractory populations, with potential for early-line use if data are positive.

• Brepocitinib positioned as a category leader in JAK inhibitors for orphan inflammatory diseases, with broad potential for additional indications.